Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials-Reference-Cited by-同舟云学术

Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials

Author:

Agarwal Rishu¹²,Dawson Mark A.¹²³⁴,Dreyling Martin⁵,Tam Constantine S.²³⁶⁷

Affiliation:

1. Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;

2. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;

3. Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;

4. Centre for Cancer Research, University of Melbourne, Parkville, Victoria, Australia;

5. Department of Medicine III, University Hospital, LMU Munich, Germany;

6. Department of Haematology, St Vincent's Hospital, Fitzroy, Victoria, Australia;

7. Department of Medicine, University of Melbourne, Parkville, Victoria, Australia

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

Reference110 articles.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献